Characteristics of LYG patients from an interim analysis of the prospective NCI study
| Characteristic . | All patients (N = 70) . |
|---|---|
| Median age (range), y | 46.2 (14.9-67) |
| Male sex, n (%) | 45 (64) |
| Histologic grade, n (%) | |
| I | 19 (27) |
| II | 24 (34) |
| III | 27 (39) |
| Disease sites, n (%) | |
| Lung | 70 (100) |
| CNS | 28 (40) |
| Skin | 24 (34) |
| Kidney | 13 (19) |
| Liver | 12 (17) |
| Spleen | 7 (10) |
| LN | 4 (6) |
| Other | 13 (19) |
| Prior therapy, n (%) | |
| None | 23 (33) |
| Steroids | 32 (46) |
| Chemotherapy with/without rituximab | 21 (30) |
| Rituximab | 13 (19) |
| Characteristic . | All patients (N = 70) . |
|---|---|
| Median age (range), y | 46.2 (14.9-67) |
| Male sex, n (%) | 45 (64) |
| Histologic grade, n (%) | |
| I | 19 (27) |
| II | 24 (34) |
| III | 27 (39) |
| Disease sites, n (%) | |
| Lung | 70 (100) |
| CNS | 28 (40) |
| Skin | 24 (34) |
| Kidney | 13 (19) |
| Liver | 12 (17) |
| Spleen | 7 (10) |
| LN | 4 (6) |
| Other | 13 (19) |
| Prior therapy, n (%) | |
| None | 23 (33) |
| Steroids | 32 (46) |
| Chemotherapy with/without rituximab | 21 (30) |
| Rituximab | 13 (19) |
LN, lymph node.